ArticleChemistry & biodiversity2026
Enzymatic Synthesis of a Novel α-Linolenic Acid-Enriched Phytoceramide From Perilla Seed Oil and Its Multifunctional Bioactivity in Skin Barrier Repair and Anti-Aging.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ceramides are essential lipid components of the skin barrier, accounting for approximately 50% of intercellular lipids in the stratum corneum. Their deficiency is associated with various skin disorders, including atopic dermatitis and xerosis. This study aimed to enzymatically synthesize a novel phytoceramide from perilla seed oil (PSO-Cer) and evaluate its multifaceted bioactivity, including skin barrier enhancement and anti-aging effects, in comparison with oleic acid-derived Ceramide IIIB. PSO-Cer was synthesized enzymatically and characterized by HPLC-CAD and LC-QTOF. Its biological effects were assessed in human keratinocytes (HaCaT) and dermal fibroblasts-adult (HDF-a) through cytotoxicity assays, qPCR of genes related to barrier function and extracellular matrix (ECM) synthesis, western blot, and transcriptome sequencing. HPLC-CAD confirmed PSO-Cer was rich in polyunsaturated fatty acid chains, notably α-linolenic acid (34.49%). Both PSO-Cer and Ceramide IIIB were non-cytotoxic up to 25 µg/mL and significantly upregulated genes critical for epidermal barrier function (FLG, IVL, TGM1, CERS3, and ELOVL4) and ECM components (COL1A1, COL3A1, and ELN) in UVB-irradiated fibroblasts. Transcriptome analysis revealed that while both ceramides shared common mechanisms, namely activation of mTOR signaling and sphingolipid metabolism, PSO-Cer exhibited distinct properties, positioning it as a promising multifunctional active for advanced skincare formulations aimed at comprehensive skin health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.